All

SumUp launches Magic Pay for the hospitality sector
21 July 2022

SumUp launches Magic Pay for the hospitality sector

SumUp, the financial partner for over 4 million small businesses worldwide, today announced the launch of SumUp Magic Pay, a QR code payment solution for the hospitality...

Read more
Launchmetrics launches visual content platform and invests in AI
20 July 2022

Launchmetrics launches visual content platform and invests in AI

Launchmetrics' expansion into the visual content sector began in 2019 with the acquisition of Italian company IMAXtree. The deal underscored the company's interest in...

Read more
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases
20 July 2022

Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet...

Read more
IDNow increases focus on offering for financial services sector in the UK
18 July 2022

IDNow increases focus on offering for financial services sector in the UK

IDnow group, a leading European provider of identity proofing and digital identities, has appointed Mike Kiely as its Sales Director for Financial Services. Based in IDnow’s...

Read more
String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).
11 July 2022

String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).

String Bio (String) and Woodside Energy are collaborating on potential production of sustainable protein ingredients from greenhouse gases.
Woodside Energy has invested...

Read the press release
Intento Design secures the third round of investment to accelerate its commercial deployment
24 June 2022

Intento Design secures the third round of investment to accelerate its commercial deployment

Intento Design, a Paris-based french company, developing and commercializing intelligent analog design automation tools to accelerate and secure chip production, announces...

Read the press release
SumUp raises $624M at $8.5B valuation, with its payments and business tech now used by 4M SMBs
23 June 2022

SumUp raises $624M at $8.5B valuation, with its payments and business tech now used by 4M SMBs

A decade ago, SumUp was one of the army of fintechs that made names for themselves with dongles that turned basic smartphones into card payment terminals. Today, the...

Read more
Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™
23 June 2022

Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™

Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy...

Read more
Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC
23 June 2022

Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC

GB1211, Galecto's galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models

Read the press release
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
6 June 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read more